drugset / Trial / NCT02273570

Optimal Anemia Treatment in End Stage Renal Disease (ERSD)

NCT02273570 ↗

RandomizedParallel-groupOpen-labelSupportive care

Summary

Clinical study aimed at improving anemia management in End Stage Renal Disease Patient (ESRD) on maintenance Hemodialysis with evidence of Chronic Kidney disease Mineral Bone Disorder (CKD-MBD)

Timeline

Start
2015-03
Primary completion
2016-12
Completion
2017-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Aluminum Phosphate Unknown — —
Background Calcitriol Small molecule — —
Background Calcium carbonate Other / unclassified — —
Background Cinacalcet Other / unclassified 90 mg —
Background Lanthanum Carbonate Other / unclassified — —
Background Magnesium carbonate Small molecule — —
Background Paricalcitol Other / unclassified 6 ug —
Background Sevelamer Other / unclassified — —
Background calcium acetate Other / unclassified — —
Background vitamin-25-OH-D Unknown 400 iu —